TotalVisc™

Viscoelastic System

Complete Solution.
Total Protection.

ClearVisc™
2.5% sodium hyaluronate

StableVisc™
1.0% sodium hyaluronate

TotalVisc™

Viscoelastic System

Complete Solution. Total Protection.

Free Radical Protection - with two dual action formulations, ClearVisc™ and StableVisc™ create a strong physical barrier, providing mechanical protection and superior free radical eradication compared to other OVDs tested in a laboratory study. [1,2,*]

*Compared to ProVisc, Viscoat, Healon Pro, Healon Endocoat, AmVisc, Amvisc Plus.

Total Protection – no other dual pack OVD system in the U.S. provides this unique complete solution, utilizing the protection of sorbitol in both ClearVisc™, dispersive and StableVisc™, cohesive.

Largest Fill Volume - TotalVisc™ leads the U.S. dual pack OVD market in fill volume of device with 1 mL of ClearVisc™ and 1 mL StableVisc™.

Sign up for your TotalVisc™ trial

ClearVisc™

2.5% sodium hyaluronate

VISUALIZE THE BENEFITS, EXPERIENCE THE DIFFERENCE

The only dispersive OVD in the U.S. with sorbitol for tissue protection

bauschsurgical.com | customerservice@bauschsurgical.com

The TotalVisc™ viscoelastic system offers the next generation complete solution with both mechanical and chemical protection provided by ClearVisc™, dispersive and StableVisc™ cohesive.

MECHANICAL PROTECTION

Both StableVisc™ and ClearVisc™ are specifically designed with a molecular weight and viscosity that optimizes endothelial cell protection.

CHEMICAL PROTECTION

Both StableVisc™ and ClearVisc™ feature a proprietary formulation of sodium hyaluronate and sorbitol to inhibit free radicals.

StableVisc™
1.0% sodium hyaluronate

NEXT GENERATION PROTECTION, PREFERRED PERFORMANCE

StableVisc™, with sorbitol is the only cohesive OVD in the U.S. offering next generation mechanical and chemical protection

Larger Fill Volume

TotalVisc™ leads the U.S. dual pack OVD market in fill volume of device with 1 mL of ClearVisc™ and 1 mL StableVisc™.





In the FDA clinical studies 26.6% of cases using StableVisc™ and 19.6% of cases using ClearVisc™ used the entire first OVD syringe during surgery compared to 42.9% of ProVisc and 29.8% of Viscoat.[3,4]

TotalVisc™
Viscoelastic System

TotalVisc™ includes one 1.0 mL of StableVisc™ and one 1.0 mL of ClearVisc™

ORDER NUMBER TVISC20

ORDER NUMBER	DVISC10
SIZE	1.0 mL
VISCOSITY, CP (AT 1S-1 SHEAR RATE, 25°C)	40,000
MOLECULAR WEIGHT (DALTONS)	<1.0 million
COMPOSITION	2.5% HA 4% sorbitol
COHESION	Dispersive
OSMOLALITY (MOSM/KG)	330
CANNULA SIZE	25G

ORDER NUMBER	SVISC10
SIZE	1.0 mL
VISCOSITY, CP (AT 1S-1 SHEAR RATE, 25°C)	50,000
MOLECULAR WEIGHT (DALTONS)	2.1 million
COMPOSITION	1.0% HA, 4% sorbitol
COHESION	Cohesive
OSMOLALITY (MOSM/KG)	340
CANNULA SIZE	27G

Sign up for your TotalVisc™ trial

bauschsurgical.com | customerservice@bauschsurgical.com

Free Radicals in Cataract Surgery

Free radicals form in the eye as a result of chemical reactions caused during cataract procedures. They can contribute to corneal damage and possible decompensation, which can lead to post-surgical complications such as a cloudy cornea.

ClearVisc™ and StableVisc™ with sorbitol chemically bonds to free radical particles to deliver a high level of free radical scavenging activity compared to other OVDs tested in a laboratory study.[1,*]

*Compared to ProVisc, Viscoat, Healon Pro, Healon Endocoat, AmVisc, Amvisc Plus.

Sorbitol chemical compound

Sorbitol + free radicals in the eye



Sorbitol neutralizing free radicals

VISUALIZATION: ClearVisc™

FDA CLINICAL STUDY OUTCOMES

100%

Clinically clear corneas at 1-week post-operative.[3]

In a wet lab survey with 6 leading cataract surgeons, regarding visualization of ocular tissue, bubbles were observed with Viscoat and not with ClearVisc™.[3]

Tissue Visibility

In a wet lab survey with 6 leading cataract surgeons, ClearVisc™ was ranked as having better tissue visibility compared to Viscoat.[3]

StableVisc™ Safety Profile

In the FDA clinical study, StableVisc™ was significantly non-inferior to ProVisc in the proportion of patients with post-operative IOP ≥ 30 mmHg at any follow-up visit. 5.2% for StableVisc™ and 8.2% for ProVisc.[4,*]

*Primary Safety Variable: Postoperative IOP



VISUALIZATION: StableVisc™

StableVisc™ is a comprehensive cohesive with the control you need.

FDA CLINICAL STUDY OUTCOMES

97%

Clinically clear corneas at 1-week post-operative.[4]

StableVisc™ was rated better for ease of removal, ability to maintain chamber stability, ease of distribution within the anterior chamber and ease of visco dissection in a wet lab survey with 6 leading cataract surgeons compared to ProVisc.[4]

In a wet lab survey with 6 leading cataract surgeons, StableVisc™ was ranked as having better tissue visibility compared to ProVisc.[4]

TotalVisc™

Viscoelastic System

Learn more at bauschsurgical.com

Indications and Important Safety Information for ClearVisc, StableVisc and TotalVisc OVDs

INDICATIONS: ClearVisc, StableVisc and TotalVisc OVDs are indicated for use as surgical aids in ophthalmic anterior segment procedures including: Extraction of a cataract; Implantation of an intraocular lens (IOL)

CONTRAINDICATIONS: There are no contraindications to the use of ClearVisc, StableVisc and TotalVisc when used as a surgical aid in ophthalmic anterior segment procedures.

PRECAUTIONS: Precautions normally considered during anterior segment procedures are recommended. Pre-existing glaucoma may place patients at risk for increases in intraocular pressure from the OVD during the early postoperative period.

WARNINGS:

- Do not use if the sterile barrier has been breached. Sterility cannot be guaranteed, and the patient will be at increased risk for infection.
- Do not use the OVD in subjects with known allergies to any of its components.
- An excess quantity of OVD should not be used. Excess OVD can cause increased intraocular pressure.
- The OVD should be removed from the anterior chamber at the end of surgery to prevent or minimize postoperative intraocular pressure increases (spikes). OVD remaining in the eye can cause increased intraocular pressure.
- If the postoperative intraocular pressure increases above expected values, corrective therapy should be administered. Increased intraocular pressure may lead to inflammation or vision loss.
- Do not re-use the cannula. Even after cleaning and rinsing, resterilized cannula could release particulate matter as the OVD is injected. It is recommended that a single-use disposable cannula be used when administering the OVD. Reuse may cause eye inflammation.
- If any particulate matter is observed, it should be removed by irrigation and/or aspiration. Particulate matter left in the eye may cause increased IOP or Light scattering /obstruction.
- Store at 2° to 8°C (36° to 46°F). Protect from freezing. The shelf life of ClearVisc, StableVisc and TotalVisc is not guaranteed if it is not properly stored.

ADVERSE REACTIONS: Sodium hyaluronate is a natural component of tissues within the body and is generally well tolerated in human eyes. Transient postoperative inflammatory reactions and increases in intraocular pressure have been reported. Inflammation may result from increased intraocular pressure caused by use of the OVD. Intraocular inflammation, i.e., toxic anterior segment syndrome (TASS), has been attributed to OVDs. Furthermore, vision loss may be possible as a result of increased intraocular pressure and inflammation.

ATTENTION: Refer to the Directions for Use labeling for a complete listing of indications, warnings and precautions, clinical trial information, etc.

CAUTION: Federal (USA) law restricts this device to the sale by or on the order of a physician.

1. Erb W., Ayyagari M., Lau G., New Ophthalmic Viscosurgical Device (OVD) with Enhanced Hydroxyl Radical Scavenging Activity. May 2021, Virtual ARVO.
2. Francesco Maugeri, Adriana Maltese, Keith W. Ward & Claudio Bucolo (2007). Hydroxyl Radical Scavenging Activity of a New Ophthalmic Viscosurgical Device, Current Eye Research, 32:2, 105-111, DOI:10.1080/02713680601147716.
3. Packer M, Berdahl JP, Goldberg DF, Hosten L, Lau G. Safety and effectiveness of a new ophthalmic viscosurgical device: randomized, controlled study. J Cataract Refract Surg. 2022 Sep 1;48(9):1050-1056.
4. Packer M, Shultz M, Loden J, Lau G. Safety and effectivenes comparison of a new cohesive ophthalmic viscosurgical device. J Cataract Refract Surg. 2023 Apr 18.

BAUSCH + LOMB